BCL2 and lymphoma: We examined the responses of sgTfap4/Eμ-MYC/Cas9 and sgControl/Eμ-MYC/Cas9 lymphoma cell lines to the BH3 mimetic drugs ABT-199/Venetoclax [34] or S63845 [35] that inhibit BCL-2 or MCL-1, respectively.